hrp0094p2-171 | Fat, metabolism and obesity | ESPE2021

Association of calprotectin with obesity in prepubertal children

Yoon Jong Seo , Young Kim Eun , Hee Yi Kyung , Suk Shim Young , Hwang IL Tae ,

Background: Perturbation of inflammation is critically linked to nutrient metabolic pathways and obesity-associated complications, such as insulin resistance and type 2 diabetes (T2DM). The S100 family of proteins, including S100A8/A9 (calprotectin), have been implicated in disease pathogenesis and investigated as potential markers of inflammation. In adults, increased circulating levels of calprotectin have been reported in obesity-related chronic low-grade i...

hrp0097p1-90 | Fetal, Neonatal Endocrinology and Metabolism | ESPE2023

Low-Dose Diazoxide Therapy in Hyperinsulinaemic Hypoglycaemia

Yi-Lin Ng Amy , Agarwal Pankaj , Vijayan Roopa , B Arya Ved , R Kapoor Ritika , Shah Pratik

Background: Diazoxide therapy is used as first line treatment in hyperinsulinaemic hypoglycaemia (HH). Apart from a single study reporting efficacy of low dose diazoxide in small for gestational age (SGA) infants, diazoxide has been reported to be used in doses of 5-20 mg/kg/day [1].Objective: To report the outcomes of infants with HH responsive to low dose diazoxide (≤5mg/kg/day).Method...

hrp0095t13 | Section | ESPE2022

Impact on predicted adult height and basal gonadotropin levels through triptorelin 6-month formulation in patients with central precocious puberty

Joo Yoo Eun , Yang Aram , Jun Choi Yong

Background: Triptorelin, a gonadotropin-releasing hormone (GnRH) agonist, is available as 1-, 3-, and 6-month formulation for treatment of central precocious puberty (CPP). The triptorelin 22.5mg as 6-month formulation, which has recently been approved for use in CPP and offers greater convenience to children by reducing the injection frequency, but related research is very limited. The aim of this study was to study on the impact of 6 month formulation on pre...

hrp0095t17 | Section | ESPE2022

Impact on predicted adult height and basal gonadotropin levels through triptorelin 6-month formulation in patients with central precocious puberty

Joo Yoo Eun , Yang Aram , 아람 양

Background: Triptorelin, a gonadotropin-releasing hormone (GnRH) agonist, is available as 1-, 3-, and 6-month formulation for treatment of central precocious puberty (CPP). The triptorelin 22.5mg as 6-month formulation, which has recently been approved for use in CPP and offers greater convenience to children by reducing the injection frequency, but related research is very limited. The aim of this study was to study on the impact of 6 month formulation on pre...

hrp0095p2-176 | Growth and Syndromes | ESPE2022

A case of 1q21 recurrent microdeletion syndrome with growth hormone deficiency, facial dysmorphism, and microcephaly

A Kim Hyun , Kim Jinsup , Ju Lee Hyun , Yang Aram

1q21.1 recurrent microdeletion syndrome is a rare chromosomal disorder caused by a genetic abnormality of non-allelic homologous recombination in the sequence of flanking a copy number variation event during meiosis. The characteristic features of 1q21 microdeletion syndrome are dysmorphic facial appearances with microcephaly, and mild to moderate developmental delay of speech and motor, eye abnormality, short stature, skeletal malformation, and psychiatric and behavioral diso...

hrp0095p2-184 | Growth and Syndromes | ESPE2022

Clinical characteristics and genetic analysis of BLM gene mutation with Bloom syndrome without facial erythema changes

Huang Hui , Yang Yu , Shuai Xia , Xiong Xiangyu , Chen Ka

Objective: To retrospectively analyze the clinical data, laboratory examination, gene test results, diagnosis and treatment of a case of small gestational age, short stature and microcephaly in the department of Endocrinology, Genetics and Metabolism of Jiangxi Children's Hospital.Methods: The detailed clinical symptoms and family history of the children and their families were evaluated. 2ml peripheral blood of the...

hrp0092p1-63 | Fat, Metabolism and Obesity | ESPE2019

Altered Gut Microbiota in Obese Children: Sex-associated Signature

Chen Ruimin , Ai Zhuanzhuan , Yang Xiaohong , Zhang Ying , Yuan Xin

Background: The incidence of obesity, especially in children, have dramatically increased over the last few decades. Recently, studies highlighted the involvement of gut microbiota in the pathophysiology of obesity. Gender-related differences have been reported in animal and adult. Nonetheless, reports related on the features of gut microbiota in children with obesity is limited and no one reported the different composition of gut microbiota at different sex o...

hrp0092p1-191 | Fat, Metabolism and Obesity (1) | ESPE2019

Effect of Probiotics Intake on Obese Children

Chen Ruimin , Ai Zhuanzhuan , Yang Xiaohong , Zhang Ying , Yuan Xin

Background: Childhood obesity has been a worrisome public health issues today. Recent studies conducted in adult populations and animals have suggested beneficial effects of probiotics on obesity, while, the experience is limited in the pediatric age group and the results are conflict.Object: The primary objective was to determine the effect of Probiotics consumption on weight change. The secondary objective was to deter...

hrp0092p1-224 | Growth and Syndromes (to include Turner Syndrome) (1) | ESPE2019

The Efficacy and Adverse Reactions of the Letrozole or Gonadotropin Releasing Hormone Analog Combined with Recombinant Human Growth Hormone in Short Pubertal Boys

Chen Ruimin , Zhang Ying , Chen Shijun , Yang Xiaohong , Yuan Xin

Objective: To explore the therapeutic effects and adverse reactions of a combination of letrozole or Gonadotropin releasing hormone analog (GnRHa) and recombinant human growth hormone (rhGH), compared with rhGH alone, in pubertal short boys.Methods: Sixty-four pubertal short boys were divided into three groups, one group were treated with rhGH (rhGH group, n=21), one group were treated with the combination o...

hrp0092p1-368 | GH and IGFs (2) | ESPE2019

Renal Complication of Hematuria and Proteinuria after Recombinant Human Growth Hormone Therapy in Children

Kim Chan Jong , Park Na Ri , Yang Eun Mi

Introduction: Treatment with recombinant human growth hormone (rhGH) is useful for growth failure in short stature children. But there are some reports of renal disease or complication occurring during rhGH treatment. GH and insulin-like growth factor-1 (IGF-1), together with other growth factors and cytokines, have important roles in adaptive morphological and functional changes in the kidney. This study was aimed to reveal the renal complication of hematuria...